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Of blood and bone: the sotatercept adventure
Severe persistent anaemia remains the most common 
problem that haematologists are facing when treating 
patients with myelodysplastic syndromes.1 New 
effective and safe drugs with an easy and simple method 
of administration are urgently needed for outpatients, 
to allow long-term treatment that improves their 
quality of life. Patients with lower-risk myelodysplastic 
syndromes generally live much longer than patients 
with higher-risk disease and thus, often have many 
consecutive treatment attempts to avoid red blood 
cell transfusions.1 The study by Rami Komrokji and 
colleagues2 published in The Lancet Haematology 
efficiently contributes to the identification of a 
therapy that can relieve anaemia in patients with 
lower-risk myelodysplastic syndromes who have had 
previous treatments. In this phase 2 dose-ranging 
study, sotatercept was administered to 74 patients 
with lower-risk myelodysplastic syndromes in whom 
previous treatment had failed and who were transfusion 
dependent. Patients had either primary resistance 
or had lost response to therapies. Overall erythroid 
haematological improvement (HI-E) was achieved by 
36 (49%; 95% CI 38–60) of the 74 patients treated 
with sotatercept of all doses; with 21 (60%; 44–75) 
of 35 patients treated with 1 mg/kg achieving HI-E. 
Notably, very few patients had cytopenias other than 
anaemia, but approximately half of the patients with 
low platelet counts or neutrophil counts achieved 
platelet or neutrophil haematological improvements. 
Sotatercept, previously known as ACE-011, is 
a hybrid molecule: a fusion protein consisting of 
the extracellular domain of the human activin 
receptor type IIA and the crystallisable domain of the 
human immunoglobulin G1 (IgG1) fragment, and is 
administered by subcutaneous injection. The erythroid-
stimulating activity of sotater cept was discovered in 
post-menopausal women treated for osteoporosis 
with sotatercept3 because of its role in the modulation 
of bone resorption and formation. In fact, sotatercept 
competes extracellularly with the ligands of the TGFβ 
superfamily, activins, and bone morphogenic proteins, 
trapping them and blocking signal transduction via the 
SMAD signalling pathway.4 This inhibition of the TGFβ 
pathway, besides bone anabolic effects, relieves the 
aberrant blockage of the transcription of genes devoted 
to stimulation of late-stage erythropoiesis characteristic 
of some subtypes of myelodysplastic syndromes, 
including subtypes with ring sideroblasts with their 
specific pathogenetic molecular feature.5 
The most intriguing aspect of sotatercept is indeed 
its mechanism of action.4 The evidence of erythroid-
stimulating and antiosteoporotic activity of this drug 
should prompt further study of the mutifaceted and 
extremely complex TGFβ pathway.6 In fact, the TGFβ 
pathway modulates different cellular functions in 
a cell type-specific and context-dependent manner 
thanks to a very fine tuning and interplay of receptors, 
co-receptors, and ligands.6 The complexity of the 
TGFβ pathway might be the reason why luspatercept 
(fusion of activinRIIB and IgG1), which has a very similar 
structure to sotatercept, does not show a completely 
overlapping spectrum of activity with sotatercept.7 
Additionally, other TGFβ pathway inhibitors such as 
galunisertib, which acts by directly binding to the same 
family of receptors, do not seem to achieve such strong 
clinical effects on erythropoieisis as do sotatercept and 
luspatercept.8 These complex mechanisms of action 
must be better understood in order to optimise therapy 
for myelodysplastic syndromes, and most probably other 
illnesses too.9
What are the clinical characteristics of the patients with 
lower-risk myelodysplastic syndromes who are sensitive 
to sotatercept? Are these in a different category to those 
who are responsive to luspatercept, and what are the 
differences in their molecular characteristics? Although 
these questions remain unanswered, some important 
results have been generated by the study of Komrokji 
and colleagues.2 For example, the HI-E response to 
sotatercept was sustained for at least 56 days without 
transfusions by seven (58%) of 12 patients with low 
transfusion burdens. On the basis of these results, 
although the sample of patients with low transfusion 
burdens was small, treatment with sotatercept should 
be started as soon as possible after erythropoiesis-
stimulating agent (ESA) failure. Regardless, responses 
were still achieved in patients who had received other 
drugs such as hypomethylating agents (21 [58%] of 
36 patients) or lenalidomide (19 [54%] of 35 patients). 
A large proportion of the patients included in the 
study had a diagnosis of refractory anaemia with ring 
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sideroblasts (≥15% ring sideroblasts; 51 [69%] of 
74 patients), and a higher proportion of these patients 
achieved HI-E (30 [59%] of 51) than that of patients 
without ring sideroblasts (four [22%] of 18 patients). 
Patients belonging to the subgroup of ring sideroblast-
positive myelodysplastic syndromes are abundant 
in all clinical studies of ESA-resistant lower-risk 
myelodysplastic syndromes,9,10 which might be because 
of their longer overall survival and early loss of response 
to ESAs. This fact could potentially bias analyses, and 
only randomised studies with larger cohorts of patients 
with myelodysplastic syndromes with and without 
ringed sideroblasts could clarify the issue. 
In the study by Komrokji and colleagues,2 sotatercept 
showed a high erythroid-stimulating activity, but 
transfusion independence of at least 56 days was reached 
only in a minority of cases (20 [27%, 95% CI 18–38] 
of 74 patients). This result is similar to those observed 
for other rescue treatments for patients with relapsed 
or refractory myelodysplastic syndromes, such as 
lenalidomide.10 The study2 also showed a higher 
proportion of patients with responses to sotatercept 
in a subgroup who had lower concentrations of 
endogenous erythropoietin, although this difference was 
not significant. However, this confirms what has been 
shown in previous studies.7,10 Furthermore, treatment-
related grade 3–4 adverse events were scarce, reported in 
four (5%) of the 74 patients.
In conclusion, sotatercept is a promising and safe 
new approach to treat anaemia in patients with lower-
risk myelodysplastic syndromes. Ameliorating anaemia 
in myelodysplastic syndromes by reversing ineffective 
erythropoiesis secondary to aberrant TGFβ stimulation is 
indeed an interesting new therapeutic avenue for these 
patients. In order to optimise this approach, a more 
detailed picture of the downstream effects of sotatercept 
and of the drugs with similar molecular targets are 
needed, and the molecular and functional characteristics 
of the dysplastic diseases that can be responsive to such 
treatments need to be clearly defined.
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